{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-096804","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.658546+00:00","generated_at":"2026-05-30T02:22:04.291720+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TherapeuticsMD narrows Q3 net loss to $567K; license revenue rises to $547K","bullets":["Net loss from continuing operations of $567K ($0.05 per share) vs. $1.4M loss ($0.13) in Q3 2023.","License revenue from Mayne agreement totaled $547K, up from negative $53K in Q3 2023.","Total operating expenses fell 18.3% YoY to $1.4M on cost reductions after royalty transition.","Cash and equivalents stood at $5.0M as of Sept 30, 2024.","Company continues to evaluate strategic alternatives including M&A or asset sale; no timeline set."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-096804","json":"https://secwatch.observer/filing/0001213900-24-096804.json","markdown":"https://secwatch.observer/filing/0001213900-24-096804.md","text":"https://secwatch.observer/filing/0001213900-24-096804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390024096804/0001213900-24-096804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390024096804/ea0220593-8k_therap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:22:04.291720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}